BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal https://www.globenewswire.com/news-release/2022/06/24/2468797/0/en/BriaCell-Anti-Cancer-Technology-Published-in-Leading-Cancer-Drug-Discovery-Journal.html • Anti-Cancer activity of BriaCells lead candidate, Bria-IMT, in advanced breast cancer patients was published in a leading peer-reviewed publication.• Bria-IMT, through a novel mechanism of action, rapidly destroyed tumors in patients who matched Bria-IMT HLA types, supporting BriaCells platform strategy of developing off-the-shelf personalized immunotherapy for multiple cancer indications.• The clinical data, previously reported, included rapid tumor reduction and extended survival.PHILADELPHIA and VANCOUVER, British Columbia, June 24, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the publication of novel scientific data and clinical data (previously reported) on BriaCells lead candidate, Bria-IMT. The abstract of the paper was published on-line in Recent Patents on Anti-Cancer Drug Discovery, a publication focused on research (where patents have been registered) in leading therapeutic areas, targets, and agents related to anti-cancer drug discovery. The publication highlights BriaCells approach to developing novel cellular immunotherapies for cancer and the safety and efficacy of Bria-IMT against advanced breast cancer in a prior clinical study through a potentially unique mechanism of action. The full text of the article will be made available.• The clinical data, previously reported, included rapid tumor reduction and extended survival.PHILADELPHIA and VANCOUVER, British Columbia, June 24, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the publication of novel scientific data and clinical data (previously reported) on BriaCells lead candidate, Bria-IMT. The abstract of the paper was published on-line in Recent Patents on Anti-Cancer Drug Discovery, a publication focused on research (where patents have been registered) in leading therapeutic areas, targets, and agents related to anti-cancer drug discovery. The publication highlights BriaCells approach to developing novel cellular immunotherapies for cancer and the safety and efficacy of Bria-IMT against advanced breast cancer in a prior clinical study through a potentially unique mechanism of action. The full text of the article will be made available.